MarketPeel
Insider Trading Intelligence
EW

Eric Warren

MLYS
CHIEF COMMERCIAL OFFICER · MINERALYS THERAPEUTICS, INC. · CIK 0001916048
FILING MIX · LIFETIME26%/74%
BUYS
10
SELLS
28
TOTAL VALUE
$4.14M
COMPANIES
2
ACTIVE SINCE
Mar 2022
HOLDINGS NOW
408,618
AVG SELL PX
$22.19
TRADE KIND
SHOWING 38 / 38
Trades · vs SPY
Loading price series…
Performance · forward returns vs SPY
27 backtested trades · 8 horizons · 10 pending
Forward-return performance of every backtestable P/S trade by Eric Warren, measured at 8 horizons from 7 days to 2 years. Deduped per economic event so co-filings count once. Excess return = trade return minus SPY return over the same window.
HORIZONTRADESWIN RATEINSIDER RETURNSPY RETURNMEAN EXCESSMEDIAN EXCESST-STAT
7d27+81.48%-4.94%-0.07%-4.86%-6.52%
14d27+59.26%-5.49%+0.14%-5.63%-6.43%
30d27+62.96%-8.62%+0.29%-8.91%-8.74%
60d27+51.85%-8.73%+1.95%-10.68%+1.89%
90d27+59.26%-8.47%+3.43%-11.89%-19.06%
180d27+59.26%-1.70%+7.46%-9.15%-18.04%
1y27+37.04%+0.01%+19.02%-19.01%+2.80%
2y27(10 pending)+70.59%-26.08%+44.75%-70.83%-93.86%
How to read this: Insider Returnis the average raw return of the filer's trades over the horizon. SPY Return is what SPY did over those same windows — reference only, not a comparison. The headline alpha number is Mean Excess = Insider − SPY; green means the filer beat SPY, red means they trailed it. Win rate is the share of individual trades where the filer beat SPY. T-statvalues above 2 mean the alpha is unlikely to be chance given the sample size. "Pending" counts trades where the horizon hasn't elapsed yet; their stats are not included in the row average.
Holdings over time
MLYS · 38,400 shares · as of Jun 26, 2026
063,219126,438189,657252,876SHARES HELD
Trading cadence · quarterly flow
BUY SELL
2022
2022
2022
2022
2023
2023
2023
2023
2024
2024
2024
2024
2025
2025
2025
2025
2026
2026
FLOW · 10 buys / 28 sellsCOVERAGE · 18 quarters
Form 4 filings · all activity
COMPANYTYPESHARESPRICEVALUEHELD AFTERTRADE DATEFILEDDETAILS
MLYS
MINERALYS THERAPEUTICS, INC.
SALE10b5-1
10b5-1 plan
104,124$25.90$2.70M38,400Jun 26, 2026Jun 30, 2026View →
MLYS
MINERALYS THERAPEUTICS, INC.
SALE
Chief Commercial Officer
104,124252,876Jun 26, 2026Jun 30, 2026View →
MLYS
MINERALYS THERAPEUTICS, INC.
PURCHASE
Chief Commercial Officer
104,124$13.24$1.38M142,524Jun 26, 2026Jun 30, 2026View →
ESPR
ESPERION THERAPEUTICS, INC.
SALE
Chief Commercial Officer
108$0.98$106370,218Apr 17, 2025Apr 21, 2025View →
ESPR
ESPERION THERAPEUTICS, INC.
SALE
Chief Commercial Officer
2,433$1.49$3.6K370,326Mar 18, 2025Mar 19, 2025View →
ESPR
ESPERION THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
191,000191,000Mar 14, 2025Mar 17, 2025View →
ESPR
ESPERION THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
213,000372,759Mar 14, 2025Mar 17, 2025View →
ESPR
ESPERION THERAPEUTICS, INC.
SALE
Chief Commercial Officer
239$1.87$446159,759Feb 19, 2025Feb 20, 2025View →
ESPR
ESPERION THERAPEUTICS, INC.
SALE
Chief Commercial Officer
123$2.26$278159,998Jan 17, 2025Jan 21, 2025View →
ESPR
ESPERION THERAPEUTICS, INC.
SALE
Chief Commercial Officer
2,234$2.43$5.4K160,121Dec 17, 2024Dec 18, 2024View →
ESPR
ESPERION THERAPEUTICS, INC.
SALE
Chief Commercial Officer
197$2.17$427162,355Nov 19, 2024Nov 20, 2024View →
ESPR
ESPERION THERAPEUTICS, INC.
SALE
Chief Commercial Officer
107$2.12$227162,552Oct 17, 2024Oct 18, 2024View →
ESPR
ESPERION THERAPEUTICS, INC.
SALE
Chief Commercial Officer
2,608$1.78$4.7K162,659Sep 17, 2024Sep 18, 2024View →
ESPR
ESPERION THERAPEUTICS, INC.
SALE
Chief Commercial Officer
211$1.95$411165,267Aug 19, 2024Aug 20, 2024View →
ESPR
ESPERION THERAPEUTICS, INC.
SALE
Chief Commercial Officer
108$2.59$279165,478Jul 17, 2024Jul 18, 2024View →
ESPR
ESPERION THERAPEUTICS, INC.
SALE
Chief Commercial Officer
2,540$2.86$7.3K165,586Jun 18, 2024Jun 20, 2024View →
ESPR
ESPERION THERAPEUTICS, INC.
SALE
Chief Commercial Officer
192$2.48$477168,126May 17, 2024May 20, 2024View →
ESPR
ESPERION THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
100,000168,318Mar 14, 2024Mar 15, 2024View →
ESPR
ESPERION THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
150,000150,000Mar 14, 2024Mar 15, 2024View →
ESPR
ESPERION THERAPEUTICS, INC.
SALE
Chief Commercial Officer
742$1.25$92468,318Sep 20, 2023Sep 21, 2023View →
ESPR
ESPERION THERAPEUTICS, INC.
SALE
Chief Commercial Officer
243$1.41$34469,060Aug 18, 2023Aug 21, 2023View →
ESPR
ESPERION THERAPEUTICS, INC.
SALE
Chief Commercial Officer
106$1.59$16869,303Jul 19, 2023Jul 20, 2023View →
ESPR
ESPERION THERAPEUTICS, INC.
SALE
Chief Commercial Officer
603$1.48$89469,409Jun 21, 2023Jun 22, 2023View →
ESPR
ESPERION THERAPEUTICS, INC.
SALE
Chief Commercial Officer
219$1.62$35670,012May 17, 2023May 18, 2023View →
ESPR
ESPERION THERAPEUTICS, INC.
SALE
Chief Commercial Officer
115$1.28$14770,231Apr 19, 2023Apr 20, 2023View →
ESPR
ESPERION THERAPEUTICS, INC.
SALE
Chief Commercial Officer
526$1.78$93770,346Mar 17, 2023Mar 20, 2023View →
ESPR
ESPERION THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
94,50094,500Mar 14, 2023Mar 15, 2023View →
ESPR
ESPERION THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
22,30070,872Mar 14, 2023Mar 15, 2023View →
ESPR
ESPERION THERAPEUTICS, INC.
SALE
Chief Commercial Officer
5,090$5.06$25.7K48,572Mar 7, 2023Mar 8, 2023View →
ESPR
ESPERION THERAPEUTICS, INC.
SALE
Chief Commercial Officer
107$7.69$82353,662Oct 18, 2022Oct 19, 2022View →
ESPR
ESPERION THERAPEUTICS, INC.
SALE
Chief Commercial Officer
255$6.92$1.8K53,769Sep 19, 2022Sep 20, 2022View →
ESPR
ESPERION THERAPEUTICS, INC.
PURCHASE
Chief Commercial Officer
1,000$7.46$7.5K54,024Aug 31, 2022Aug 31, 2022View →
ESPR
ESPERION THERAPEUTICS, INC.
SALE
Chief Commercial Officer
199$6.82$1.4K53,024Aug 17, 2022Aug 18, 2022View →
ESPR
ESPERION THERAPEUTICS, INC.
SALE
Chief Commercial Officer
431$6.58$2.8K53,223Jul 19, 2022Jul 20, 2022View →
ESPR
ESPERION THERAPEUTICS, INC.
SALE
Chief Commercial Officer
256$4.90$1.3K53,654Jun 17, 2022Jun 21, 2022View →
ESPR
ESPERION THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
52,00052,000Jun 7, 2022Jun 9, 2022View →
ESPR
ESPERION THERAPEUTICS, INC.
SALE
Chief Commercial Officer
196$5.98$1.2K53,910May 17, 2022May 18, 2022View →
ESPR
ESPERION THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
13,00054,106Mar 14, 2022Mar 16, 2022View →
Other insiders · MLYS
Loading peer insiders…
About this filer
CIK 0001916048
ROLE
Chief Commercial Officer
PRIMARY
MLYS
COMPANIES
2
ACTIVE SINCE
Mar 2022
MARKETPEEL · /INSIDER/0001916048DATA · SEC EDGAR · FORM 4 · CONSOLIDATED TAPE
FREE · DAILY · 6 AM ET

One short email. Insider buys, congressional trades, and plain-English analysis.

Feedback